Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection

Journal of Infectious Diseases

Volumn 216, Issue 11, 2017, Pages 1398-1406

  Capella, Cristina ^a   Chaiwatpongsakorn, Supranee ^a   Gorrell, Erin ^a,c   Risch, Zachary A ^a,d   Ye, Fang ^a   Mertz, Sara E ^a   Johnson, Sara M ^a   Moore Clingenpeel, Melissa ^a   Ramilo, Octavio ^a,b   Mejias, Asuncion ^a,b   Peeples, Mark E ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c KENT STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antibodies; Infant; PrefusionRSV; Severity

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MATERNAL ANTIBODY; POSTFUSION F ANTIBODY; PREFUSION F ANTIBODY; THROMBOSPONDIN ANTIBODY; UNCLASSIFIED DRUG; G GLYCOPROTEIN, RESPIRATORY SYNCYTIAL VIRUS; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

AGE; ANTIBODY BLOOD LEVEL; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS NEUTRALIZATION; A-549 CELL LINE; BLOOD; CELL LINE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT; OHIO;

A549 CELLS; AGE FACTORS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; OHIO; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS;

EID: 85038014572     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix489     Document Type: Conference Paper

References (40)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-anal-ysis. Lancet 2010; 375:1545-55.
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282:1440-6.
3. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012; 31:5-9.
4. Sanchez-Luna M, Elola FJ, Fernandez-Perez C, Bernal JL, Lopez-Pineda A. Trends in respiratory syncytial virus bron-chiolitis hospitalizations in children less than 1 year: 2004-2012. Curr Med Res Opin 2016; 32:693-8.
5. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-128.
6. IMpact-RSV Study Group. Palivizumab, a humanized res-piratory syncytial virus monoclonal antibody, reduces hos-pitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7.
7. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008; 317:103-23.
8. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21:3479-82.
9. Shinof JJ, O'Brien KL, Tumar B, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008; 198:1007-15.
10. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syn-cytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009; 123:398-403.
11. Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specifc antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015; 7:309ra162.
12. Magro M, Mas V, Chappell K, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein ofer unique possibilities for clinical inter-vention. Proc Natl Acad Sci USA 2012; 109:3089-94.
13. Palomo C, Mas V, Tom M, et al. Influence of respiratory syncytial virus F glycoprotein conformation on induction of protective immune responses. J Virol 2016; 90:5485-98.
14. McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. In: Anderson JL, Graham SB, eds. Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013:83-104.
15. Melero JA, Moore ML. Influence of respiratory syncytial virus strain diferences on pathogenesis and immunity. Curr Top Microbiol Immunol 2013; 372:59-82.
16. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708-15.
17. Hacimustafaoglu M, Celebi S, Aynaci E, et al. The progression of maternal RSV antibodies in the ofspring. Arch Dis Child 2004; 89:52-3.
18. Ochola R, Sande C, Fegan G, et al. The level and duration of RSV-specifc maternal IgG in infants in Kilif Kenya. PLoS One 2009; 4:e8088.
19. Sande CJ, Mutunga MN, Okiro EA, Medley GF, Cane PA, et al. Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort. J Med Virol 2013; 85:2020-5.
20. Stensballe LG, Ravn H, Kristensen K, Meakins T, Aaby P, et al. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009; 154:296-8.
21. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Grifn MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000; 137:865-70.
22. Saso A, Kampmann B. Vaccination against respiratory syn-cytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? Lancet Infect Dis 2016; 16:e153-63.
23. Kaaijk P, Luytjes W, Rots NY. Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Hum Vaccin Immunother 2013; 9:1263-7.
24. Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Curr Opin Infect Dis 2015; 28:221-4.
25. Heinonen S, Jartti T, Garcia C, et al. Rhinovirus detection in symptomatic and asymptomatic children: value of host transcriptome analysis. Am J Respir Crit Care Med 2016; 193:772-82.
26. de Steenhuijsen Piters WA, Heinonen S, Hasrat R, et al. Nasopharyngeal microbiota, host transcriptome, and disease severity in children with respiratory syncytial virus infection. Am J Respir Crit Care Med 2016; 194:1104-15.
27. Mella C, Suarez-Arrabal MC, Lopez S, et al. Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 2013; 207:564-73.
28. García C, Soriano-Fallas A, Lozano J, et al. Decreased innate immune cytokine responses correlate with disease severity in children with respiratory syncytial virus and human rhi-novirus bronchiolitis. Pediatr Infect Dis J 2012; 31:86-9.
29. Mejias A, Dimo B, Suarez NM, et al. Whole blood gene expression profiles to assess pathogenesis and disease severity in infants with respiratory syncytial virus infection. PLoS Med 2013; 10:e1001549.
30. Fuentes S, Crim RL, Beeler J, Teng MN, Golding H, et al. Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following respiratory syncytial virus vaccination and infection. Vaccine 2013; 31:3987-94.
31. McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specifc neutralizing antibody. Science 2013; 340:1113-7.
32. Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME. Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity bufer. J Virol 2011; 85:3968-77.
33. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody afnity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15:34-41.
34. Polack FP, Hofman SJ, Crujeiras G, Grifn DE. A role for nonprotective complement-fxing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003; 9:1209-13.
35. Freitas GR, Silva DA, Yokosawa J, et al. Antibody response and avidity of respiratory syncytial virus-specifc total IgG, IgG1, and IgG3 in young children. J Med Virol 2011; 83:1826-33.
36. Chu HY, Steinhof MC, Magaret A, et al. Respiratory syn-cytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 2014; 210:1582-9.
37. Suara RO, Piedra PA, Glezen WP, et al. Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States. Clin Diagn Lab Immunol 1996; 3:477-9.
38. Nyiro JU, Sande C, Mutunga M, et al. Quantifying maternally derived respiratory syncytial virus specifc neutralising antibodies in a birth cohort from coastal Kenya. Vaccine 2015; 33:1797-801.
39. Jans J, Wicht O, Widjaja I, et al. Characteristics of RSV-specifc maternal antibodies in plasma of hospitalized, acute RSV patients under three months of age. PLoS One 2017; 12:e0170877.
40. Johnson SM, McNally BA, Ioannidis I, et al. Respiratory syn-cytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog 2015; 11:e1005318.